Meningioma

Pharmacological restoration of histone acetylation with the HDAC inhibitor Trichostatin A (TSA) effectively suppressed tumor growth. Collectively, our findings identify KMT2C as a key epigenetic regulator linking promoter histone acetylation, NF2-Hippo pathway activity, and ferroptosis susceptibility. These results provide mechanistic insights into high-grade meningioma progression and highlight ferroptosis induction and epigenetic modulation as promising therapeutic strategies for NF2-wild-type, KMT2C-deficient meningiomas.

Combining molecular and radiological parameters could improve neurosurgical planning and perioperative management. Further studies are needed regarding the assessment of the response to anti-edematous therapies in low and high FOXC1 expressing meningiomas.

These findings offer an extensive resource on the cellular heterogeneity of the meningioma microenvironment and provide a framework for rational therapeutic modeling and strategy development.

P1/2, N=38, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Mar 2027

RIMs predominantly align with the hypermetabolic molecular group, characterized by metabolic pathway activation and genomic instability. This distribution indicates a distinct molecular profile compared with sporadic meningiomas.

ONSM represents a predominantly NF2-intact meningioma subtype defined by neural niche-associated transcriptional signatures. Although typically indolent, ONSM can, in rare instances, evolve into an aggressive disease through further accumulation of CNVs.

Senolytic plus senogenic combinations demonstrate robust preclinical efficacy in reducing tumor growth and senescent burden while promoting apoptosis across diverse in vivo models. These findings highlight senotherapy as a promising adjunct to conventional senescence-inducing anticancer therapies and underscore the need for standardized in vivo methodologies and translational studies to guide clinical application. This review protocol was prospectively registered on PROSPERO (registration number: CRD420251161998).

P=N/A, N=140, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

Schwannomas exhibit minimal [Ga68]DOTATATE avidity, in contrast to SSTR2-expressing tumors such as meningiomas. [Ga68]DOTATATE PET may therefore aid in non-invasively differentiating schwannomas from SSTR2-expressing tumors with overlapping MRI features in diagnostically challenging cases.

P=N/A, N=238, Not yet recruiting, Centre Hospitalier St Anne

Considering the availability of PPAR modulatory drugs, it may be an important therapeutic target. In addition, the meticulous examination of the brain invasion still holds significant promise for prognostication.

Particular emphasis is placed on advances in dosimetry, quantitative imaging, and radiomics, which are beginning to refine patient selection and improve response prediction. Together, current evidence highlights the therapeutic potential of radionuclide therapy in aggressive or refractory meningiomas and underscores the need for further prospective trials to define its optimal clinical application.